Bayer gets “green light” for new transparent low dose contraceptive patch in the EU

14 February 2014

Germany’s Bayer (BAYN: DE) says it has successfully concluded the decentralized European registration procedure for its new transparent low dose contraceptive patch (gestodene/ethinylestradiol).

The Health Authorities of the European Union member states will now grant national approvals for the product. Bayer Healthcare filed for EU approval of the patch in 2012 (The Pharma Letter September 21, 2012).

“The new contraceptive patch will provide women with an additional choice of a low dose contraceptive,” said Jorg Moller, a member of the Bayer HealthCare executive committee and head of global development.

Would compete with J&J’s Evra

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK